Ipamorelin Research Guide: GHSR Mechanism, Human Data, and Negative Results
Ipamorelin Research Guide: GHSR Mechanism, Human Data, and Negative Results
A balanced review of ipamorelin ghrelin-receptor pharmacology, early GH biomarker work, gastrointestinal models, and a negative controlled human trial.
Ipamorelin's receptor activity does not guarantee an outcome
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue studied at the growth-hormone secretagogue receptor, now usually called the ghrelin receptor or GHSR. It is pharmacologically different from GHRH analogs such as CJC-1295 or sermorelin.
Foundational work used rat pituitary cells, rats, and swine to characterize GH release and relative hormonal selectivity. A small human study modeled acute pharmacokinetic and GH-response relationships, while rodent work later examined postoperative ileus.
The important translational check is a randomized human phase 2 trial in bowel-resection patients: prespecified key and secondary efficacy analyses did not significantly differ from placebo. That negative result should be prominent.
What researchers are trying to understand
Is ipamorelin a GHRH analog?
No. It is a GHSR or ghrelin-receptor agonist, whereas CJC-1295 and sermorelin act through the GHRH receptor.
What does selective GH release mean?
Foundational animal work reported relative hormone selectivity under its test conditions. It does not establish clinical selectivity, safety, or benefit in all settings.
What did the controlled human trial find?
The phase 2 postoperative-ileus study found no significant difference between ipamorelin and placebo on key and secondary efficacy analyses.
Notable studies, in plain English
The studies below are separated by model and design so that early laboratory signals are not confused with evidence from people.
Ipamorelin, the first selective growth hormone secretagogue
- Model
- Animal and in vitro
- Design
- Rat pituitary-cell experiments plus anesthetized-rat and conscious-swine pharmacology.
What the paper reported: The study reported GH release and relative selectivity against several other measured pituitary or adrenal hormones in the tested models.
Important limit: Multi-species preclinical selectivity does not establish human outcomes or broad safety.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
- Model
- Human
- Design
- Small early-phase study in healthy men modeling plasma exposure and acute GH response.
What the paper reported: The paper characterized a time-linked exposure and GH-biomarker relationship.
Important limit: Small groups and a surrogate hormonal endpoint do not establish a clinical or performance benefit.
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus
- Model
- Rat
- Design
- Surgical intestinal-manipulation model measuring colonic transit and related postoperative endpoints.
What the paper reported: The authors reported pro-motility-associated changes in the rat model.
Important limit: A rodent surgery model cannot establish human efficacy and was followed by a negative controlled clinical efficacy result.
Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
- Model
- Human
- Design
- Multicenter, randomized, double-blind, placebo-controlled phase 2 trial; 117 participants enrolled.
What the paper reported: There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
Important limit: The trial was small and condition-specific, but its negative efficacy result directly limits translation from the positive rodent model.
What the evidence does—and does not—establish
Most supportive pharmacology is animal, in vitro, or based on an acute GH biomarker. Those data do not establish body-composition, recovery, sleep, performance, or anti-aging outcomes.
The controlled human efficacy trial did not show significant improvement in its key or secondary analyses. A faithful guide should use this as a central translational result, not a footnote.
GHSR activity also differs from GHRH-receptor activity. Product bundles or comparison pages should not merge the mechanisms or imply that combining compounds has established efficacy.
- Ipamorelin is a GHSR agonist, not a GHRH analog.
- Foundational selectivity evidence is largely preclinical.
- The human PK/PD paper used an acute GH biomarker.
- The phase 2 human efficacy result was negative.
- No study validates a supplier's current lot.
Where to buy Ipamorelin for laboratory research in the USA
A research listing should disclose the pentapeptide sequence including nonstandard residues and amidation, the salt form, theoretical and observed mass, chromatographic purity, labeled quantity, and lot number.
Review the lot-specific COA, underlying chromatogram, test date, storage documentation, fulfillment origin, and support contact. Procurement copy should include the negative human efficacy result in the evidence guide and avoid GH-outcome promises.
Searches such as “where to buy Ipamorelin,” “buy Ipamorelin USA,” and “USA peptides” should be treated as laboratory-sourcing questions. Compare U.S. research suppliers by lot traceability, identity testing, quantitative-content information, analytical methods, and stated research-use restrictions—not by implied human outcomes.
Ipamorelin research FAQ
What receptor does ipamorelin target?
It is studied as an agonist at GHSR, the growth-hormone secretagogue or ghrelin receptor.
Is ipamorelin the same type of peptide as CJC-1295?
No. Ipamorelin targets GHSR, while CJC-1295 is a modified GHRH-receptor agonist.
Did ipamorelin succeed in the phase 2 postoperative-ileus trial?
No significant differences were found between ipamorelin and placebo in the key and secondary efficacy analyses.
Does acute GH release prove muscle or recovery effects?
No. A short-term hormone response is a surrogate biomarker, not a durable clinical or performance outcome.
What should an ipamorelin COA show?
It should link a specific lot to the stated modified sequence, observed mass, chromatographic purity, test date, and responsible test method or laboratory.
Primary references
References link to the original journal record or publisher page. Inclusion is not an endorsement of a product or a clinical conclusion.
- Raun K et al. European Journal of Endocrinology. 1998;139:552-561. PMID 9849822. DOI 10.1530/eje.0.1390552.
- Gobburu JVS et al. Pharmaceutical Research. 1999;16:1412-1416. PMID 10496658. DOI 10.1023/A:1018955126402.
- Venkova K et al. Journal of Pharmacology and Experimental Therapeutics. 2009;329:1110-1116. PMID 19289567. DOI 10.1124/jpet.108.149211.
- Beck DE et al. International Journal of Colorectal Disease. 2014;29:1527-1534. PMID 25331030. DOI 10.1007/s00384-014-2030-8.